EGFR and cancer: However, as with most other molecular-targeted drugs, the major issues concerning the use of anti-EGFR agents (monoclonal antibodies, small molecule inhibitors, etc) for chemoprevention are their high costs for prolonged use and associated toxicity, especially given that the majority of patients offered chemopreventive agents do not have cancer.